253 related articles for article (PubMed ID: 10907424)
21. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
Misra R; Malik A; Singhal S
Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
[TBL] [Abstract][Full Text] [Related]
22. Antifungal activity of amphotericin B and itraconazole against filamentous fungi: comparison of the Sensititre Yeast One and NCCLS M38--a reference methods.
Carrillo-Muñoz AJ; Quindós G; Del Valle O; Hernández-Molina JM; Santos P
J Chemother; 2004 Oct; 16(5):468-73. PubMed ID: 15565914
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility-testing in Aspergillus species.
Lass-Flörl C; Perkhofer S
Mycoses; 2008 Sep; 51(5):437-46. PubMed ID: 18422914
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of five antifungal agents against pathogenic Exophiala species.
Li D; Li R; Wang D; Ma S
Chin Med J (Engl); 1999 Jun; 112(6):484-8. PubMed ID: 11601322
[TBL] [Abstract][Full Text] [Related]
25. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
26. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
J Antimicrob Chemother; 1999 Oct; 44(4):553-5. PubMed ID: 10588320
[TBL] [Abstract][Full Text] [Related]
27. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
28. In vitro susceptibility testing in Aspergillus species: an update.
Lass-Flörl C
Future Microbiol; 2010 May; 5(5):789-99. PubMed ID: 20441550
[TBL] [Abstract][Full Text] [Related]
29. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
[TBL] [Abstract][Full Text] [Related]
30. Antifungal susceptibility of the aspergillus species by Etest and CLSI reference methods.
Badiee P; Alborzi A; Moeini M; Haddadi P; Farshad S; Japoni A; Ziyaeyan M
Arch Iran Med; 2012 Jul; 15(7):429-32. PubMed ID: 22724880
[TBL] [Abstract][Full Text] [Related]
31. Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole.
Ozkutuk A; Ergon C; Metin DY; Yucesoy M; Polat SH
J Chemother; 2008 Feb; 20(1):87-92. PubMed ID: 18343749
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the Sensititre YeastOne colorimetric microdilution panel and the NCCLS broth microdilution method for antifungal susceptibility testing against Candida species.
Bernal S; Aller AI; Chávez M; Valverde A; Serrano C; Gutiérrez MJ; Quindós G; Martín Mazuelos E
Chemotherapy; 2002 Mar; 48(1):21-5. PubMed ID: 11901252
[TBL] [Abstract][Full Text] [Related]
33. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility of Aspergillus strains from culture collections to amphotericin B and itraconazole.
Rath PM
J Antimicrob Chemother; 1998 May; 41(5):567-70. PubMed ID: 9630411
[TBL] [Abstract][Full Text] [Related]
35. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
Escribano P; Peláez T; Recio S; Bouza E; Guinea J
Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886
[TBL] [Abstract][Full Text] [Related]
36. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.
Espinel-Ingroff A; Bartlett M; Chaturvedi V; Ghannoum M; Hazen KC; Pfaller MA; Rinaldi M; Walsh TJ
Antimicrob Agents Chemother; 2001 Jun; 45(6):1828-35. PubMed ID: 11353633
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins.
Martos AI; Romero A; González MT; González A; Serrano C; Castro C; Pemán J; Cantón E; Martín-Mazuelos E
Med Mycol; 2010 Sep; 48(6):858-61. PubMed ID: 20144131
[TBL] [Abstract][Full Text] [Related]
38. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.
Te Dorsthorst DT; Verweij PE; Meis JF; Punt NC; Mouton JW
Antimicrob Agents Chemother; 2004 Jun; 48(6):2007-13. PubMed ID: 15155192
[TBL] [Abstract][Full Text] [Related]
39. [In vitro sensitivity tests for yeasts: evaluation of a micromethod].
Rodero LL; Davel GO; Vivot W; Canteros CE; Fernández C
Rev Argent Microbiol; 1995; 27(2):81-9. PubMed ID: 8552761
[TBL] [Abstract][Full Text] [Related]
40. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole.
Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW;
Clin Microbiol Infect; 2012 Jul; 18(7):E248-50. PubMed ID: 22540149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
